Clinical Trial Update: Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating regorafenib in bevacizumab-refractory recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Recurrent Glioblastoma | Phase 2 | Status: COMPLETED